Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 1974-1982

  Jacobs, Timothy W ^a   Gown, Allen M ^a   Yaziji, Hadi ^a   Barnes, Melissa J ^a   Schnitt, Stuart J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; ONCOPROTEIN HER 2 NEU; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0033055699     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.1974     Document Type: Article

References (80)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Tandon AK, Clark GM, Chamness GC, et al: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989
4. Thor AD, Schwartz LH, Koerner FC, et al: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49:7147-7152, 1989
5. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
6. Borg A, Tandon AK, Sigurdsson H, et al: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337, 1990
7. Lovekin C, Ellis IO, Locker A, et al: c-erbB-2 oncoprotein expression in primary and advanced breast cancer [published erratum appears in Br J Cancer 64:202, 1991]. Br J Cancer 63:439-443, 1991
8. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
9. Winstanley J, Cooke T, Murray GD, et al: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63:447-450, 1991
10. McCann AH, Dervan PA, O'Regan M, et al: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296-3303, 1991
11. Rilke F, Colnaghi MI, Cascinelli N, et al: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49, 1991
12. O'Reilly SM, Barnes DM, Camplejohn RS, et al: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63:444-446, 1991
13. Anbazhagan R, Gelber RD, Bettelheim R, et al: Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 2:47-53, 1991
14. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
15. Toikkanen S, Helin H, Isola J, et al: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol 10:1044-1048, 1992
16. Noguchi M, Koyasaki N, Ohta N, et al: C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69:2953-2960, 1992
17. Tiwari RK, Borgen PI, Wong GY, et al: HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12:419-425, 1992
18. Gasparini G, Gullick WJ, Bevilacqua P, et al: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features [see comments]. J Clin Oncol 10:686-695, 1992
19. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936-1942, 1993
20. Hartmann LC, Ingle JN, Wold LE, et al: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: Results from a randomized adjuvant treatment protocol. Cancer 74:2956-2963, 1994
21. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359-2365, 1994
22. Quenel N, Wafflart J, Bonichon F, et al: The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases. Breast Cancer Res Treat 35:283-291, 1995
23. Ro JS, el-Naggar A, Ro JY, et al: c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49:6941-6944, 1989
24. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
25. Dykins R, Corbett IP, Henry JA, et al: Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163:105-110, 1991
26. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991
27. Paterson MC, Dietrich KD, Danyluk J, et al: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51:556-567, 1991
28. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
29. Bianchi S, Paglierani M, Zampi G, et al: Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 67:625-629, 1993
30. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
31. Giai M, Roagna R, Ponzone R, et al: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 14:1441-1450, 1994
32. Rosen PP, Lesser ML, Arroyo CD, et al: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75:1320-1326, 1995
33. O'Malley FP, Saad Z, Kerkvliet N, et al: The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol 27:955-963, 1996
34. Albanell J, Bellmunt J, Molina R, et al: Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res 16:1027-1032, 1996
35. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
36. Andrulis IL, Bull SB, Blackstein ME, et al: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J Clin Oncol 16:1340-1349, 1998
37. Ross JS, Muraca PJ, Jaffe D, et al: Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 11.26A, 1998 (abstr)
38. Cobleigh MA, Vogel CL, Tripathy D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemother-apy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97A, 1998 (abstr 376)
39. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)
40. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
41. Stal O, Sullivan S, Wingren S, et al: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995
42. Bitran JD, Samuels B, Trujillo Y, et al: Her2/neu Overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 2:1509-1513, 1996
43. Tetu B, Brisson J, Plante V, et al: p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 11:823-830, 1998
44. Muss HB, Thor AD, Berry DA. et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
45. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
46. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
47. Ravdin PM, Green S, Albain KS, et al: Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with Tamoxifen (T) alone. Proc Am Soc Clin Oncol 17:97A, 1998 (abstr 374)
48. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
49. Borg A, Baldetorp B, Ferno M, et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144, 1994
50. Carlomagno C, Perrone F, Gallo C, et al: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996
51. Sjogren S, Inganas M, Lindgren A, et al: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
52. Naber SP, Tsutsumi Y, Yin S, et al: Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. Am J Clin Pathol 94:125-136, 1990
53. Kallioniemi OP, Kallioniemi A, Kurisu W, et al: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 89:5321-5325, 1992
54. Descotes F, Pavy JJ, Adessi GL: Human breast cancer: Correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 13:119-124, 1993
55. Gramlich TL, Cohen C, Fritsch C, et al: Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Am J Clin Pathol 101:493-499, 1994
56. Youngson BJ, Anelli A, Van Zee KJ, et al: Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma. Am J Surg Pathol 19:1354-1358, 1995
57. Smith KL, Robbins PD, Dawkins HJ, et al: c-erbB-2 amplification in breast cancer: Detection in formalin-fixed, paraffin-embedded tissue by in situ hybridization. Hum Pathol 25:413-418, 1994
58. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
59. Persons DL, Borelli KA, Hsu PH: Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10:720-727, 1997
60. Dittadi R, Brazzale A, Pappagallo G, et al: ErbB2 assay in breast cancer: Possibly improved clinical information using a quantitative method. Anticancer Res 17:1245-1247, 1997
61. Singleton TP, Niehans GA, Gu F, et al: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23:1141-1150, 1992
62. Kerns BJ, Jordan PA, Huper G, et al: Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol 6:673-678, 1993
63. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
64. Bobrow LG, Happerfield LC, Millis RR: Comparison of immunohistological staining with different antibodies to the c-erbB-2 oncoprotein. Appl Immunohistochem 4:128-134, 1996
65. Ratcliffe N, Wells W, Wheeler K, et al: The combination of in situ hybridization and immunohistochemical analysis: An evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol 10:1247-1252, 1997
66. Couturier J, Nicolas A, Beuzeboc P, et al: High correlation between ERBB2 amplification detected by FISH and gene overexpression detected by immuno-histochemistry in breast cancers. Mod Pathol 12: 18A, 1999 (abstr)
67. Ashfaq R, Frenkel E, Saliger F, et al: HER-2/neu oncogene overexpression: Comparison of immunohistochemistry (IHC) with fluorescent in situ hybridization assay (FISH). Mod Pathol 12:15A, 1999 (abstr)
68. Dabbs DJ, Mangini J, Shackney S, et al: Discordance between flow cytometric (FCM) quantitation of HER-2/neu, FISH amplification and semiquantitative immunohistochemistry (IHC) in breast carcinomas. Mod Pathol 12:18A, 1999 (abstr)
69. Jimenez RE, Wallis T, Tabaczka P, et al: Fluorescent in situ hybridization (FISH) vs immunohistochemistry (IHC) for determination of HER-2/neu status in breast cancer. Mod Pathol 12:23A , 1999 (abstr)
70. Oncor: Oncor INFORM HER-2/neu Gene Detection System: Procedure and Interpretation Guide. Gaithersburg, MD, Oncor, Inc. 1998
71. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer - Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
72. Clark GM: Prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, 1996, pp 461-85
73. Ciocca DR, Fujimura FK, Tandon AK, et al: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers [see comments]. J Natl Cancer Inst 84:1279-1282, 1992
74. Szollosi J, Balazs M, Feuerstein BG, et al: ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400-5407, 1995
75. Bacus SS, Bacus JW, Slamon DJ, et al: HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med 114:164-169, 1990
76. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
77. Kay EW, Walsh CJ, Cassidy M, et al: C-erbB-2 immunostaining: Problems with interpretation. J Clin Pathol 47:816-822, 1994
78. Busmanis I, Feleppa F, Jones A, et al: Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology 26:261-267, 1994
79. Ross JS, Fletcher JA: The HER-2/neu oncoprotein in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 3:237-252, 1998
80. Haerslev T, Jacobsen GK: Microwave processing of formalin-fixed and paraffin-embedded sections improves the immunoreactivity of c-erbB-2 oncoprotein in breast carcinoma. Appl Immunohistochem 1:223-226, 1993